Double figure growth continues for PharmaNutra S.p.A.
The Board of Directors approves the draft balance sheet and consolidated financial statement as of 31 December 2019.
€53.6 M Net Revenue (+15% compared to 2018)
€13.2 M EBITDA (+12% compared to 2018 restated)
€8.5 M Net Income (+8% compared to 2018 restated)
€13.6 M Cash Assets (+2.2% compared to 31.12.2018)
€0.46 M Proposed ordinary unit dividend per share
PharmaNutra S.p.A. hereby informs that the Board of Directors has examined and approved the draft financial statement on 31ˢᵗ December 2019 and consolidated financial statement as of 31ˢᵗ December 2019, drawn up in accordance with the Issuers’ Regulations AIM Italia/Mercato Alternative of the Shareholding and in conformity with the international accounting principles IFRS.
Andrea Lacorte, President of PharmaNutra S.p.A, commented: “The financial year results show an important step forward in the growth that has always featured in the progress of our company. Even while experiencing a complicated situation on a global scale, due to the spread of COVID-19, PharmaNutra continues to achieve significant results: financially, as can be seen in the balance sheet data, in terms of sales, thanks to sales data constantly on the increase, and lastly in scientific terms, with an impressive four new formulas in advanced stages of development and scientific validation, including in particular one specifically for strengthening the immune system. PharmaNutra has not stopped, and continues to grow, invest and believe in research and its own ambitious objectives”.
Roberto Lacorte, Vice President of PharmaNutra, confirmed that: “Another financial year has closed with growth in line with the trends of previous years, while showing much stronger numbers. We have gone through a year of constant expansion, by reinforcing the three main growth channels: stipulating new foreign distribution contracts, strengthening the sales network in Italy and investing in communications. Thanks to a solid financial structure and the company’s current position on the market, PharmaNutra is working with an eye to the future, managing critical aspects with care and reactively, on the strength of a solid heritage and robust revenue capacity. After an extraordinary start in the first two months of the year, PharmaNutra is currently not only maintaining its position on the market but working to be even stronger and more productive as soon as the effects of COVID-19 pass”.
The consolidated financial statement as of 31ᵗʰ December 2019 will be made available to the public according to the terms and methods envisaged by the Issuer Regulations AIM Italia, as well as on the Internet site of PharmaNutra S.p.A. in the section “Investor Relations”.
Tuesday 24ᵗʰ March, at 18:00 CET the results of the financial year 2019 will be presented by the Management to analysts and institutional investors. The web conference presenting the results can be followed live at the link: http://bit.ly/PHN_2019ResultsConference.
The meeting will be held by Andrea Lacorte (President), Roberto Lacorte (VP and CEO), Carlo Volpi (COO) and Francesco Sarti (CFO).
Click here to read the complete Press Release and the Group accounting prospectus.